Novice

Prilenia’s Pridopidine for Huntington’s Disease Accepted for European Marketing Authorisation Review

3. september 2024

Prilenia, a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, has filed a European Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for pridopidine as a treatment for Huntington’s disease (HD). An MAA

Preberite več "

Chronicle of a Relentless Quest: The Making of a Foundation

avgust 1, 2024

I belong to the third generation of a family affected by Huntington’s Disease, but it wasn’t until 2024, thanks to the tireless efforts of my second father, F. Cook, that we were able to confirm how the disease entered the family. My maternal great-grandfather, a Frenchman named Charles Novel-Catin (1883-1936),

Preberite več "

IROS, Prilenia and International Huntington’s Disease Association collaborate on first-ever Huntington’s disease (HD) trial in the MENA region

julij 11, 2024

Abu Dhabi, UAE; June 19, 2024: IROS, an Abu Dhabi-based contract research organization (part of the M42 group), has partnered with Prilenia Therapeutics, a clinical-stage biotech company, and the International Huntington’s Disease Association (IHA) to plan the first-ever clinical trial for Huntington’s disease (HD) in the UAE and MENA region,

Preberite več "

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for HD

julij 9, 2024

“We are very pleased with these new data demonstrating a statistically significant, dose-dependent slowing of the progression of Huntington’s disease and lowering of NfL in the CSF at 24 months,” stated Walid Abi-Saab, M.D., chief medical officer of uniQure. “We believe this is the first clinical trial of any investigational medicine

Preberite več "

Družba Wave Life Sciences napoveduje pozitivne rezultate preskušanja faze 1b/2a SELECT-HD s prvim kliničnim dokazom alelno selektivnega znižanja vrednosti mutiranega huntingtina pri Huntingtonovi bolezni

25. junij 2024

Družba Wave Life Sciences je danes objavila pozitivne rezultate raziskave SELECT-HD, našega s placebom nadzorovanega preskušanja faze 1b/2a, v katerem se ocenjuje raziskovalna terapija WVE-003. Ti rezultati kažejo, da zdravilo WVE-003 selektivno zmanjšuje toksični, mutantni huntingtin (mHTT) in ohranja zdrav, divji huntingtin (wtHTT) pri posameznikih s Huntingtonovo boleznijo. Rezultati preskušanja V analizi so primerjali

Preberite več "

Novosti z Bližnjega vzhoda in severne Afrike

3. junij 2024

Predsednik IHA Svein Olaf Olsen je bil glavni govornik o Huntingtonovi bolezni na kongresu MENA za redke bolezni v Abu Dabiju prejšnji mesec. Govoril je o nujni potrebi po vzpostavitvi centra odličnosti za nevrodegenerativne bolezni v regiji in spodbujanju kliničnih raziskav. To se popolnoma ujema z namenom regije

Preberite več "

Obstajamo: Tanita Allen pripoveduje o svojem boju za dostop do genetskega testiranja v Združenih državah Amerike

maj 18, 2024

Tanita Allen v svojih spominih z naslovom "We Exist" (Obstajamo) pripoveduje o težavah, ki jih je imela pri postavljanju pravilne diagnoze Huntingtonove bolezni. Vedno znova so ji postavljali napačne diagnoze, ker zdravniki niso hoteli upoštevati, da lahko mutirani gen podedujejo tudi Afroameričani. V svojih spominih se je lotila močnega raziskovanja

Preberite več "

Prilenia’s Pridopidine for Huntington’s Disease Accepted for European Marketing Authorisation Review

3. september 2024

Prilenia, a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, has filed a European Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for pridopidine as a treatment for Huntington’s disease (HD). An MAA

Preberite več "

Chronicle of a Relentless Quest: The Making of a Foundation

avgust 1, 2024

I belong to the third generation of a family affected by Huntington’s Disease, but it wasn’t until 2024, thanks to the tireless efforts of my second father, F. Cook, that we were able to confirm how the disease entered the family. My maternal great-grandfather, a Frenchman named Charles Novel-Catin (1883-1936),

Preberite več "

IROS, Prilenia and International Huntington’s Disease Association collaborate on first-ever Huntington’s disease (HD) trial in the MENA region

julij 11, 2024

Abu Dhabi, UAE; June 19, 2024: IROS, an Abu Dhabi-based contract research organization (part of the M42 group), has partnered with Prilenia Therapeutics, a clinical-stage biotech company, and the International Huntington’s Disease Association (IHA) to plan the first-ever clinical trial for Huntington’s disease (HD) in the UAE and MENA region,

Preberite več "

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for HD

julij 9, 2024

“We are very pleased with these new data demonstrating a statistically significant, dose-dependent slowing of the progression of Huntington’s disease and lowering of NfL in the CSF at 24 months,” stated Walid Abi-Saab, M.D., chief medical officer of uniQure. “We believe this is the first clinical trial of any investigational medicine

Preberite več "

Družba Wave Life Sciences napoveduje pozitivne rezultate preskušanja faze 1b/2a SELECT-HD s prvim kliničnim dokazom alelno selektivnega znižanja vrednosti mutiranega huntingtina pri Huntingtonovi bolezni

25. junij 2024

Družba Wave Life Sciences je danes objavila pozitivne rezultate raziskave SELECT-HD, našega s placebom nadzorovanega preskušanja faze 1b/2a, v katerem se ocenjuje raziskovalna terapija WVE-003. Ti rezultati kažejo, da zdravilo WVE-003 selektivno zmanjšuje toksični, mutantni huntingtin (mHTT) in ohranja zdrav, divji huntingtin (wtHTT) pri posameznikih s Huntingtonovo boleznijo. Rezultati preskušanja V analizi so primerjali

Preberite več "

Novosti z Bližnjega vzhoda in severne Afrike

3. junij 2024

Predsednik IHA Svein Olaf Olsen je bil glavni govornik o Huntingtonovi bolezni na kongresu MENA za redke bolezni v Abu Dabiju prejšnji mesec. Govoril je o nujni potrebi po vzpostavitvi centra odličnosti za nevrodegenerativne bolezni v regiji in spodbujanju kliničnih raziskav. To se popolnoma ujema z namenom regije

Preberite več "

Obstajamo: Tanita Allen pripoveduje o svojem boju za dostop do genetskega testiranja v Združenih državah Amerike

maj 18, 2024

Tanita Allen v svojih spominih z naslovom "We Exist" (Obstajamo) pripoveduje o težavah, ki jih je imela pri postavljanju pravilne diagnoze Huntingtonove bolezni. Vedno znova so ji postavljali napačne diagnoze, ker zdravniki niso hoteli upoštevati, da lahko mutirani gen podedujejo tudi Afroameričani. V svojih spominih se je lotila močnega raziskovanja

Preberite več "
sl_SISlovenian
en_USEnglish arArabic bg_BGBulgarian zh_CNChinese cs_CZCzech da_DKDanish nl_NLDutch etEstonian fiFinnish fr_FRFrench de_DEGerman elGreek hu_HUHungarian id_IDIndonesian it_ITItalian jaJapanese lvLatvian lt_LTLithuanian pl_PLPolish pt_PTPortuguese ro_RORomanian ru_RURussian sk_SKSlovak es_ESSpanish sv_SESwedish tr_TRTurkish ukUkrainian sl_SISlovenian
Preskoči na vsebino